A study by researchers at the University of North Carolina Eshelman School of Pharmacy and Lineberger Comprehensive Cancer Center determined the cost savings for a generic version of an orally administered cancer treatment were less than expected—a finding that questions the impact generic drugs can have on controlling health care costs.
↧